HSPC-sparing treatments for RB-positive abnormal cellular proliferation
This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
1. A method for treating retinoblastoma (Rb)-positive breast cancer in a host comprising administering an effective amount of a compound to a host in need thereof, wherein the compound is
or a pharmaceutically acceptable salt thereof, and wherein the compound is administered to the host at least once a day for 28 or more continuous days.
2. The method of claim 1 , wherein the host is a human.
3. The method of claim 2 , wherein the compound is administered orally.
4. The method of claim 2 , further comprising administering to the host at least one additional chemotherapeutic agent during the treatment regimen.
5. The method of claim 2 , wherein the breast cancer is estrogen-receptor positive.
6. The method of claim 1 , wherein the compound is administered at least once a day for 35 or more continuous days.
7. The method of claim 4 , wherein the additional chemotherapeutic agent is selected from tamoxifen, letrozole, anastrozole, toremifene, and trastuzumab.
8. The method of claim 2 , wherein the compound is administered once a day.
9. The method of claim 4 , wherein the additional chemotherapeutic agent is tamoxifen.
10. The method of claim 4 , wherein the additional chemotherapeutic agent is letrozole.
11. The method of claim 4 , wherein the additional chemotherapeutic agent is anastrozole.
12. The method of claim 4 , wherein the additional chemotherapeutic agent is toremifene.
13. The method of claim 4 , wherein the additional chemotherapeutic agent is trastuzumab.
14. The method of claim 2 , wherein the Rb-positive breast cancer is estrogen receptor positive, HER2-negative advanced breast cancer.
15. The method of claim 2 , wherein the Rb-positive breast cancer is HER2-positive breast cancer.